Canada Life’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$40K Sell
8,914
-71,287
-89% -$371K ﹤0.01% 1782
2025
Q4
$493K Sell
80,201
-6,367
-7% -$46.2K ﹤0.01% 1510
2025
Q3
$625K Buy
86,568
+1,346
+2% +$7.99K ﹤0.01% 1560
2025
Q2
$452K Sell
85,222
-9,931
-10% -$58.7K ﹤0.01% 1629
2025
Q1
$845K Sell
95,153
-14,825
-13% -$178K ﹤0.01% 1482
2024
Q4
$1.51M Sell
109,978
-700
-0.6% -$12.9K ﹤0.01% 1361
2024
Q3
$3.03M Sell
110,678
-3,355
-3% -$90.8K 0.01% 1112
2024
Q2
$2.79M Buy
114,033
+10,535
+10% +$231K 0.01% 1114
2024
Q1
$2.2M Buy
103,498
+7,123
+7% +$153K ﹤0.01% 1199
2023
Q4
$1.84M Buy
96,375
+1,276
+1% +$22.1K ﹤0.01% 1285
2023
Q3
$1.52M Sell
95,099
-56
-0.1% -$1.07K ﹤0.01% 1336
2023
Q2
$2.21M Sell
95,155
-3,134
-3% -$68.4K 0.01% 1148
2023
Q1
$2.28M Sell
98,289
-6,026
-6% -$122K 0.01% 1163
2022
Q4
$1.51M Buy
104,315
+2,249
+2% +$41.9K ﹤0.01% 1365
2022
Q3
$1.95M Buy
102,066
+20,219
+25% +$464K 0.01% 1194
2022
Q2
$1.49M Buy
81,847
+10,153
+14% +$211K ﹤0.01% 1296
2022
Q1
$1.85M Buy
71,694
+1,711
+2% +$43.8K ﹤0.01% 1239
2021
Q4
$1.93M Buy
69,983
+2,414
+4% +$69.9K ﹤0.01% 1217
2021
Q3
$2.2M Sell
67,569
-377
-0.6% -$12.5K 0.01% 1121
2021
Q2
$2.07M Buy
67,946
+1,399
+2% +$40.4K ﹤0.01% 1131
2021
Q1
$2.03M Sell
66,547
-8,521
-11% -$242K ﹤0.01% 1138
2020
Q4
$1.48M Sell
75,068
-10,959
-13% -$177K ﹤0.01% 1309
2020
Q3
$1.12M Sell
86,027
-8,462
-9% -$107K ﹤0.01% 1362
2020
Q2
$1.07M Sell
94,489
-5,846
-6% -$83K ﹤0.01% 1411
2020
Q1
$1.43M Buy
100,335
+6,942
+7% +$147K ﹤0.01% 1116
2019
Q4
$2.52M Buy
+93,393
New +$2.57M 0.01% 993
2019
Q3
Sell
-97,224
Closed -$2.7M 1838
2019
Q2
$2.7M Sell
97,224
-1,157
-1% -$32.7K 0.01% 992
2019
Q1
$3.26M Sell
98,381
-761
-0.8% -$23.2K 0.01% 794
2018
Q4
$2.66M Buy
99,142
+9,944
+11% +$358K 0.01% 869
2018
Q3
$4.1M Sell
89,198
-2,184
-2% -$97.1K 0.01% 776
2018
Q2
$3.41M Sell
91,382
-1,378
-1% -$46.5K 0.01% 855
2018
Q1
$2.74M Buy
92,760
+1,858
+2% +$62.9K 0.01% 953
2017
Q4
$3.12M Sell
90,902
-3,984
-4% -$134K 0.01% 891
2017
Q3
$3.43M Sell
94,886
-5,808
-6% -$166K 0.01% 831
2017
Q2
$2.6M Buy
100,694
+3,180
+3% +$67.5K 0.01% 962
2017
Q1
$1.87M Buy
97,514
+88,301
+958% +$1.56M 0.01% 1183
2016
Q4
$154K Hold
9,213
﹤0.01% 1983
2016
Q3
$189K Hold
9,213
﹤0.01% 1919
2016
Q2
$281K Hold
9,213
﹤0.01% 1799
2016
Q1
$345K Buy
9,213
+2,674
+41% +$101K ﹤0.01% 1033
2015
Q4
$282K Hold
6,539
﹤0.01% 1101
2015
Q3
$246K Hold
6,539
﹤0.01% 1141
2015
Q2
$222K Hold
6,539
﹤0.01% 1324
2015
Q1
$231K Buy
6,539
+1,979
+43% +$70.8K ﹤0.01% 1274
2014
Q4
$155K Hold
4,560
﹤0.01% 1452
2014
Q3
$177K Sell
4,560
-36
-0.8% -$1.34K ﹤0.01% 1288
2014
Q2
$178K Buy
4,596
+36
+0.8% +$1.34K ﹤0.01% 1200
2014
Q1
$155K Hold
4,560
﹤0.01% 1220
2013
Q4
$96K Buy
+4,560
New +$115K ﹤0.01% 1430

Other funds holding MYGN

Canada Life's MYGN Position: Q1 2026 in Review

Canada Life reduced its Myriad Genetics (MYGN) stake by 89% in Q1 2026, selling an estimated $371K and leaving 8,914 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #1782.

Canada Life first reported a position in MYGN in Q4 2013 and has held it in 49 quarters since. The position peaked at $4.1M in Q3 2018. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Canada Life held 8,914 shares of Myriad Genetics worth $40K as of Q1 2026.
  • Canada Life sold 71,287 Myriad Genetics shares in Q1 2026, an estimated $371K.
  • Myriad Genetics made up ﹤0.01% of Canada Life's portfolio in Q1 2026, its #1782 holding.
  • Canada Life first reported a position in Myriad Genetics in Q4 2013 and has held it in 49 quarters since.
  • Canada Life's Myriad Genetics position peaked at $4.1M in Q3 2018.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.